According to FutureWise analysis the market for Actinic Keratosis Treatment in 2023 is US$ 5.79 billion, and is expected to reach US$ 10.11 billion by 2031 at a CAGR of 7.20%.
Actinic keratosis (AK), often referred to as solar keratosis, is a common skin ailment marked by rough, scaly areas on the skin that appear after prolonged exposure to ultraviolet (UV) radiation, mainly from the sun. Although AK is a precancerous condition in and of itself, if ignored, it can lead to squamous cell carcinoma (SCC), a form of skin cancer. The accumulated harm done to skin cells by UV radiation is the fundamental underlying cause of actinic keratosis. The cells that make up the skin's outermost layer, keratinocytes, develop abnormally as a result of this injury. This aberrant cell buildup causes the actinic keratosis-related rough, scaly patches to appear. Since only a small percentage of actinic keratosis lesions can potentially develop into skin cancer squamous cell carcinoma (SCC) if left untreated, actinic keratosis is considered a precancerous disease. Not all actinic keratosis lesions, though, will develop into cancer. Actinic keratosis can be stopped from developing into SCC with regular monitoring and the right therapy.
The market for medicines and therapies used in managing and treating actinic keratosis is referred to as the actinic keratosis treatment market. This market offers a variety of therapies, such as topical drugs, treatments, and tools made to get rid of or eradicate precancerous lesions. One of the most common approaches to treating actinic keratosis is the use of topical medications. These medications work by directly targeting and eliminating abnormal cells when applied to the affected skin. Common topical medications include Topical 5-fluorouracil (5-FU) chemotherapeutic agent selectively destroys abnormal cells. It causes a localized reaction, leading to the shedding of the damaged skin. Imiquimod functions as an immune response modifier which activates the immune system to target and remove abnormal cells. Ingenol mebutate is derived from a plant extract. This medication causes cell death and inflammation, leading to the clearance of actinic keratosis lesions. In addition to topical medications, several procedures and devices are used to treat actinic keratosis. These options are typically employed when the lesions are larger or more widespread. Some common treatment modalities include Cryotherapy, Photodynamic therapy (PDT), and Laser therapy.
FutureWise Market Research has published a report that provides an insightful analysis of the actinic keratosis treatment market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.
According to the analysis conducted by FutureWise research analysts, the actinic keratosis treatment market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.